How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,431 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Faecal transplant effectively treats recurrent or unresponsive Clostridium difficile

studies. Faecal transplant techniques varied: lower or upper bowel application, fresh or frozen stools, and one or more infusion. Donors were family members and healthy volunteers, screened for viruses and gut problems. Follow up ranged from 10 weeks to eight years. Many studies used reduction in diarrhoea as a marker of effectiveness, rather than C. difficile toxin levels. The randomised trials were assessed as low risk of bias. Including case series, the range of interventions used and variation (...) included seven randomised controlled trials of 428 participants and 30 case series of 1,545 participants. Most studies looked at older adults; some included children and younger people with weakened immune systems. There were no UK based studies. Faecal transplant techniques varied: lower or upper bowel application, fresh or frozen stools, and one or more infusion. Donors were family members and healthy volunteers, screened for viruses and gut problems. Follow up ranged from 10 weeks to eight years

2019 NIHR Dissemination Centre

142. ENDURALIFE powered CRT-D devices for treating heart failure

powered CRT-D devices for treating heart failure (MTG33) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 26Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 17 System impact 17 5 Cost considerations 18 Cost evidence 18 6 Conclusions 25 7 Committee members and NICE project team 26 (...) Committee members 26 NICE project team 26 ENDURALIFE powered CRT-D devices for treating heart failure (MTG33) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 261 1 Recommendations Recommendations 1.1 The case for adopting ENDURALIFE-powered cardiac resynchronisation therapy-defibrillator (CRT-D) devices for treating heart failure is supported by the published evidence. Extended battery life is of clinical

2017 National Institute for Health and Clinical Excellence - Medical technologies

143. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

of Appraisal Committee's key conclusions 42 5 Implementation 48 6 Recommendations for further research 50 7 Review of guidance 51 8 Appraisal Committee members, guideline representatives and NICE project team 52 Appraisal Committee members 52 NICE project team 53 9 Sources of evidence considered by the Committee 55 About this guidance 57 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373) © NICE 2019. All rights reserved. Subject to Notice of rights (https (...) Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Abatacept, adalimumab, etanercept and Abatacept, adalimumab, etanercept and tocilizumab for treating juv tocilizumab for treating juvenile enile idiopathic arthritis idiopathic arthritis T echnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

144. Elosulfase alfa for treating mucopolysaccharidosis type Iva

and Personal Social Services 28 Value for money 30 Impact of the technology beyond direct health benefits and on delivery of the specialised service 36 Conclusion 37 Summary of Evaluation Committee's key conclusions 38 6 Implementation 45 7 Review of guidance 46 8 Evaluation Committee members, guideline representatives and NICE project team 47 Evaluation Committee members 47 NICE project team 48 9 Sources of evidence considered by the Committee 49 About this guidance 52 Elosulfase alfa for treating (...) be exacerbated by limitations on income caused by difficulty working. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 52MPS IVa also significantly affects the families of people with the condition. Many parents struggle to continue working as care needs increase. Patient groups highlighted testimonies from families involved in clinical trials

2016 National Institute for Health and Clinical Excellence - Highly specialised technology

145. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts

-of-rights). Page 2 of 36Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 Clinical effectiveness 6 Cost effectiveness 11 ERG's comments 12 ERG's exploratory analysis 14 4 Committee discussion 17 Clinical effectiveness 18 Cost effectiveness 20 Summary of appraisal committee's key conclusions 26 5 Implementation 34 6 Appraisal committee members and NICE project team 35 Appraisal committee members 35 NICE project team 35 Azacitidine for treating acute myeloid leukaemia with more than 30 (...) Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts Azacitidine for treating acute m Azacitidine for treating acute my yeloid eloid leukaemia with more than 30% bone leukaemia with more than 30% bone marrow blasts marrow blasts T echnology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta399 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

146. Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation

Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation Lumacaftor–ivacaftor for treating cystic Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del fibrosis homozygous for the F508del mutation mutation T echnology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta398 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) , to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

147. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene

and depression of knowing their child will probably die at a young age. The devastating impact of the disease and its prognosis often leads to isolation from friends and family members. Parents and carers described the financial impact of looking after a person with DMD. They described giving up work to look after their child full time. In addition, out-of- pocket expenses can be very high (for example, moving house to ensure the home is wheelchair accessible). Ataluren for treating Duchenne muscular (...) for money 32 Impact of the technology beyond direct health benefits and on the delivery of the specialised service 36 Conclusion 37 Summary of evaluation committee's key conclusions 39 6 Implementation 45 7 Evaluation committee members and NICE project team 46 Evaluation committee members 46 NICE project team 46 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2016 National Institute for Health and Clinical Excellence - Highly specialised technology

148. Pegaspargase for treating acute lymphoblastic leukaemia

discussion 9 Clinical management of acute lymphoblastic leukaemia 9 Clinical effectiveness 11 Cost effectiveness 14 Innovation 17 Pharmaceutical Price Regulation Scheme (PPRS) 2014 17 Summary of appraisal committee's key conclusions 18 5 Implementation 25 6 Appraisal committee members and NICE project team 26 Appraisal committee members 26 NICE project team 26 Pegaspargase for treating acute lymphoblastic leukaemia (TA408) © NICE 2018. All rights reserved. Subject to Notice of rights (https (...) . Pegaspargase for treating acute lymphoblastic leukaemia (TA408) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 25 of 276 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

149. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Radium-223 dichloride for treating Radium-223 dichloride for treating hormone-relapsed prostate cancer with hormone-relapsed prostate cancer with bone metastases bone metastases T echnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta412 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

150. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy

members 59 NICE project team 62 8 Sources of evidence considered by the Committee 63 About this guidance 65 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 66This guidance replaces TA175 and TA162. 1 1 Guidance Guidance 1.1 Erlotinib is recommended as an option for treating locally advanced (...) Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy Erlotinib and gefitinib for treating non- Erlotinib and gefitinib for treating non- small-cell lung cancer that has small-cell lung cancer that has progressed after prior chemother progressed after prior chemotherap apy y T echnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374 © NICE 2018. All rights reserved. Subject to Notice of rights (https

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

151. Trifluridine-tipiracil for previously treated metastatic colorectal cancer

of 23Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 4 Committee discussion 7 Patients' perspective 7 Position in the treatment pathway 7 Clinical effectiveness 8 Cost effectiveness 10 End-of-life considerations 12 Pharmaceutical Price Regulation Scheme 2014 14 Summary of appraisal committee's key conclusions 14 5 Implementation 21 6 Appraisal committee members and NICE project team 22 Appraisal committee members 22 NICE project team 22 Trifluridine–tipiracil for previously treated (...) by patients and their families. 4.1 Clinical need of patients, including the availability of alternative treatments The committee was aware that there is no positive NICE guidance on third- or subsequent-line treatments. 4.2 The technology The technology Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 15 of 23The patient experts stated

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

152. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer

Appraisal committee members 28 NICE project team 28 Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 291 1 Recommendations Recommendations 1.1 Ramucirumab, in combination with docetaxel, is not recommended within its marketing authorisation for treating locally advanced or metastatic non-small- cell lung cancer (...) Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer Ramucirumab for pre Ramucirumab for previously treated viously treated locally advanced or metastatic non-small- locally advanced or metastatic non-small- cell lung cancer cell lung cancer T echnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta403 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

153. Degarelix for treating advanced hormone-dependent prostate cancer

Evidence 6 4 Committee discussion 7 Clinical effectiveness 9 Cost effectiveness 17 Summary of appraisal committee's key conclusions 25 5 Implementation 36 6 Recommendations for research 37 7 Appraisal committee members and NICE project team 38 Appraisal committee members 38 NICE project team 38 Degarelix for treating advanced hormone-dependent prostate cancer (TA404) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 (...) Degarelix for treating advanced hormone-dependent prostate cancer Degarelix for treating advanced Degarelix for treating advanced hormone-dependent prostate cancer hormone-dependent prostate cancer T echnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta404 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

154. Bosutinib for previously treated chronic myeloid leukaemia

Committee discussion 7 Clinical effectiveness 9 Cost effectiveness 12 Cancer Drugs Fund reconsideration 22 End-of-life considerations 24 Equality issues 25 Summary of appraisal committee's key conclusions 25 5 Implementation 34 6 Appraisal committee members and NICE project team 35 Appraisal committee members 35 NICE project team 35 Bosutinib for previously treated chronic myeloid leukaemia (TA401) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) ). Bosutinib for previously treated chronic myeloid leukaemia (TA401) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 362 2 The technology The technology Description of Description of the technology the technology Bosutinib (Bosulif, Pfizer) is a second-generation tyrosine kinase inhibitor that inhibits Abl-kinases, including Bcr-Abl kinase. It also inhibits the Src family kinases, which have been implicated

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

155. Belimumab for treating active autoantibody-positive systemic lupus erythematosus

Belimumab for treating active autoantibody-positive systemic lupus erythematosus Belimumab for treating activ Belimumab for treating active e autoantibody-positiv autoantibody-positive systemic lupus e systemic lupus erythematosus erythematosus T echnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

156. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma

/terms-and- conditions#notice-of-rights). Page 2 of 26Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 Clinical effectiveness 6 Cost effectiveness 8 4 Committee discussion 13 Clinical effectiveness 13 Cost effectiveness 16 Summary of appraisal committee's key conclusions 19 5 Implementation 25 6 Appraisal committee members and NICE project team 26 Appraisal committee members 26 NICE project team 26 Trametinib in combination with dabrafenib for treating unresectable or metastatic (...) , 4.15 Current pr Current practice actice Clinical need of patients, including the availability of alternative treatments The committee concluded that the availability of a new combination treatment that slows disease progression and improves quality of life is very important to patients and their families. 4.1 The technology The technology Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396) © NICE 2018. All rights reserved. Subject to Notice of rights

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

157. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

The technology The technology 2.1 Evolocumab (Repatha, Amgen) is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme involved in down- regulation of low-density lipoprotein receptors. This increases receptor density and lowers low-density lipoprotein cholesterol (LDL -C). Evolocumab has a marketing authorisation in the UK for treating adults with primary hypercholesterolaemia (heterozygous-familial and non-familial) or mixed dyslipidaemia, as an adjunct (...) ). The company modelled the 2 non-familial hypercholesterolaemia populations based on the characteristics of the respective populations in LAPLACE-2 with or without CVD. However, it only used data from the subset of patients who had an LDL -C concentration over 2.5 mmol/litre to represent a population at high risk of CVD. For patients with heterozygous-familial hypercholesterolaemia, the company used the modified intention-to-treat population in RUTHERFORD-2. 3.18 The intervention modelled in the base case

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

158. Adalimumab for treating moderate to severe hidradenitis suppurativa

3 Evidence 7 Clinical effectiveness 7 Cost effectiveness 10 Key issues 13 New evidence submitted by the company after consultation 16 Key issues 18 4 Committee discussion 22 Clinical management 22 Clinical effectiveness 25 Cost effectiveness 26 Summary of appraisal committee's key conclusions 33 5 Implementation 41 6 Appraisal committee members, guideline representatives and NICE project team 42 Appraisal committee members 42 NICE project team 42 Adalimumab for treating moderate to severe (...) Adalimumab for treating moderate to severe hidradenitis suppurativa Adalimumab for treating moder Adalimumab for treating moderate to ate to se sev vere hidr ere hidradenitis suppur adenitis suppurativa ativa T echnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

159. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

conclusions 40 5 Implementation 47 6 Recommendations for research 48 7 Appraisal committee members, guideline representatives and NICE project team 49 NICE project team 49 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 501 1 Recommendations Recommendations 1.1 Alirocumab is recommended as an option for treating primary (...) OPTIONS I was a randomised, double-blind study in 355 people with non-familial hypercholesterolaemia or heterozygous-familial hypercholesterolaemia and a history of coronary heart disease, risk of cardiovascular disease or diabetes with target organ damage, whose LDL -C levels were not adequately controlled with atorvastatin 20 mg to 40 mg. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

160. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Committee discussion 31 Clinical effectiveness 32 Cost effectiveness 34 Summary of appraisal committee's key conclusions 38 5 Implementation 45 6 Appraisal committee members and NICE project team 46 Appraisal committee members 46 NICE project team 46 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 471 1 (...) Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes Canagliflozin, dapagliflozin and Canagliflozin, dapagliflozin and empagliflozin as monother empagliflozin as monotherapies for apies for treating type 2 diabetes treating type 2 diabetes T echnology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta390 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>